Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025)
Kazia Therapeutics (KZIA) posted Total Non-Current Liabilities of $178697.5 for Q4 2025, down 9.48% on a QoQ basis from $197405.8 in Q2 2025, and down 94.75% year-over-year from $3.4 million in Q4 2024.
Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Kazia Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $178697.5 for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 94.75% year-over-year to $178697.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $178697.5 (down 94.75% YoY) and the FY2025 annual result came in at $197405.8, down 94.84% from the prior year.
- Total Non-Current Liabilities was $178697.5 for Q4 2025 at Kazia Therapeutics, down from $197405.8 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.2 million in Q2 2021 and bottomed at $178697.5 in Q4 2025.
- A 5-year average of $5.1 million and a median of $5.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities surged 261.49% — and 2025, when it slumped 94.84%.
- Kazia Therapeutics' Total Non-Current Liabilities stood at $8.4 million in 2021, then slipped by 16.92% to $7.0 million in 2022, then declined by 27.76% to $5.1 million in 2023, then plunged by 32.76% to $3.4 million in 2024, then slumped by 94.75% to $178697.5 in 2025.
- Business Quant data shows KZIA's Total Non-Current Liabilities at $178697.5 in Q4 2025, $197405.8 in Q2 2025, and $3.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Kazia Therapeutics | 4.11 Mn | 4.11 Mn | - | 178,697.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 178,697.54 |
| Jun 30, 2025 | 197,405.85 |
| Dec 31, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Dec 31, 2021 | 8.44 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Dec 31, 2020 | 3.81 Mn |
| Jun 30, 2020 | 2.54 Mn |
| Dec 31, 2019 | 3.52 Mn |
| Jun 30, 2019 | 3.56 Mn |
| Dec 31, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.82 Mn |
| Jun 30, 2017 | 3.90 Mn |
| Dec 31, 2016 | 3.74 Mn |
| Jun 30, 2016 | 3.87 Mn |
| Dec 31, 2015 | 1.17 Mn |